Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia

Purpose of reviewThe management of dyslipidemia in patients with diabetes is a key component of cardiovascular risk reduction. In particular, the atherogenic dyslipidemia of diabetes often requires combination therapy to target aspects of the lipid profile beyond low-density lipoprotein cholesterol. This article will review the characteristics of dyslipidemia in diabetes, and discuss guidelines and strategies for treatment to reduce cardiovascular disease risk. Recent findingsA number of clinical outcomes trials supports the use of statins to reduce cardiovascular events in patients with type 2 diabetes mellitus. The disappointing results of clinical trials involving torcetrapib to increase high-density lipoprotein levels may lead to renewed interest and utilization of niacin for the management of atherogenic dyslipidemia. Long-term use of fibrate therapy in patients with atherogenic dyslipidemia has recently been associated with reduction in all-cause, cancer, and cardiovascular mortality rates. Ongoing trials are investigating whether addition of niacin or fibrate to statin therapy is superior to statin therapy alone in preventing cardiovascular events. SummaryAggressive low-density lipoprotein control continues to be the primary goal of therapy in dyslipidemia management. Given the growing body of evidence showing the cardiovascular benefits of treating other lipid components, however, it is easy to anticipate that full normalization of the lipid profile may become the standard of care for diabetic dyslipidemia.

[1]  J. Armitage,et al.  The safety of statins in clinical practice , 2007, The Lancet.

[2]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[3]  A. Gotto,et al.  HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. , 2007, The New England journal of medicine.

[4]  P. Boyle.  Diabetes mellitus and macrovascular disease: mechanisms and mediators. , 2007, The American journal of medicine.

[5]  Diederick E Grobbee,et al.  Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial , 2007, The Lancet.

[6]  F. Raal,et al.  A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population , 2007, Cardiovascular journal of Africa.

[7]  C. Ballantyne,et al.  Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. , 2007, Clinical therapeutics.

[8]  R. Parker,et al.  Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2 , 2007, Nature.

[9]  Lawrence A Leiter,et al.  Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. , 2007, The American journal of cardiology.

[10]  W. Cushman,et al.  Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. , 2007, The American journal of cardiology.

[11]  Jennifer G. Robinson,et al.  Safety of aggressive lipid management. , 2007, Journal of the American College of Cardiology.

[12]  D. Grobbee,et al.  Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia , 2007 .

[13]  Jean-Claude Tardif,et al.  Effect of torcetrapib on the progression of coronary atherosclerosis. , 2007, The New England journal of medicine.

[14]  H. Bays,et al.  Safety considerations with niacin therapy. , 2007, The American journal of cardiology.

[15]  F. Hobbs,et al.  Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control. , 2006, International journal of cardiology.

[16]  L. Tenkanen,et al.  Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. , 2006, Archives of internal medicine.

[17]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[18]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[19]  Jeannie K. Lee,et al.  Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins , 2004, Circulation.

[20]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[21]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[22]  A. Tall,et al.  A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly Published, JLR Papers in Press, February 16, 2004. DOI 10.1194/jlr.M300520-JLR200 , 2004, Journal of Lipid Research.

[23]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[24]  R. Collins,et al.  Heart Protection Study , 2003, The Lancet.

[25]  Allen J. Taylor,et al.  ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A Randomized Trial Comparing the Effects of Atorvastatin and Pravastatin on Carotid Intima Medial Thickness , 2002, Circulation.

[26]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[27]  E. Bolson,et al.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.

[28]  A. Sharrett,et al.  Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions: The Atherosclerosis Risk in Communities (ARIC) Study , 2001, Circulation.

[29]  J. Wittes,et al.  Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001, JAMA.

[30]  Diabetes Atherosclerosis Intervention Study Investigators.  Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study , 2001, The Lancet.

[31]  Bezafibrate Infarction Prevention study.  Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.

[32]  S. Haffner,et al.  Secondary prevention of coronary heart disease: the role of fibric acids. , 2000, Circulation.

[33]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[34]  D. Capuzzi,et al.  A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. , 1998, The American journal of cardiology.

[35]  B. Davis,et al.  Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. , 1998, Circulation.

[36]  Barry J. Davis,et al.  Effect of Pravastatin on Cardiovascular Events in Older Patients with Myocardial Infarction and Cholesterol Levels in the Average Range: Results of the Cholesterol and Recurrent Events (CARE) Trial , 1998, Annals of Internal Medicine.

[37]  R. Holman,et al.  Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) , 1998, BMJ.

[38]  A. von Eckardstein,et al.  High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. , 1996, Atherosclerosis.

[39]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[40]  J. Neaton,et al.  Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.

[41]  W. Castelli.  Epidemiology of triglycerides: a view from Framingham. , 1992, The American journal of cardiology.

[42]  H. Ginsberg.  Lipoprotein Physiology in Nondiabetic and Diabetic States: Relationship to Atherogenesis , 1991, Diabetes Care.

[43]  G. Assmann,et al.  The Prospective Cardiovascular Münster Study: prevalence and prognostic significance of hyperlipidemia in men with systemic hypertension. , 1987, The American journal of cardiology.

[44]  G. Reaven,et al.  Reduced plasma high density lipoprotein-cholesterol concentrations need not increase when hyperglycemia is controlled with insulin in noninsulin-dependent diabetes mellitus. , 1986, The Journal of clinical endocrinology and metabolism.

[45]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.

[46]  Ralph,et al.  The Coronary Drug Project: Design, Methods, and Baseline Results , 1973, Circulation.

[47]  W. Howard.  Effect of Torcetrapib on the Progression of Coronary Atherosclerosis , 2008 .

[48]  G. Keating,et al.  Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. , 2007, Drugs.

[49]  S. Schwartz,et al.  Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. , 2007, Clinical therapeutics.

[50]  R. Nesto.  Beyond Low-Density Lipoprotein , 2005, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[51]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[52]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.